Zobrazeno 1 - 10 of 60 pro vyhledávání: '"Giunta EF"'
1
Identification of a highly suppressive Treg subset associated with immunotherapy response
Autor: Troiani T, Romano Simona, D'Arrigo P, Rea A, Tufano M, Giunta EF, Matarese G, Procaccini C, Novizio N, Vigorito V, Faicchia D, Argenziano G, Ciardiello F, Romano MF.
Melanoma often exploits Treg to avoid immune attack. Treg is a heterogeneous population with respect to immunosuppressive capability. Lymphocytes are particularly rich in FKBP51 (encoded by FKBP5 gene), known as the receptor for FK506. Melanoma aberr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3730::d2ec878d6a985e90a4853875466104dd
http://hdl.handle.net/11588/749008
Zobrazit plný text záznamu
3
Akademický článek
Pharmacological treatment landscape of non-metastatic hormone-sensitive prostate cancer: A narrative review on behalf of the meet-URO Group.
Autor: Giunta EF; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Roviello G; Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Firenze, Firenze, Italy., Conteduca V; Unit of Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences, University of Foggia, Policlinico Riuniti, Foggia, Italy., Verzoni E; SSD Genitourinary Medical Oncology and Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Procopio G; SSD Genitourinary Medical Oncology and Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., De Giorgi U; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy. Electronic address: ugo.degiorgi@irst.emr.it.
Publikováno v: Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2024 Oct 22; Vol. 204, pp. 104534. Date of Electronic Publication: 2024 Oct 22.
Zobrazit plný text záznamu
4
Akademický článek
Correlation of [ 68 Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients.
Autor: Giunta EF; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy. emiliofrancescogiunta@gmail.com., Caroli P; Department of Nuclear Medicine, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Scarpi E; Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Altavilla A; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Rossetti V; Department of Nuclear Medicine, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Marini I; Department of Nuclear Medicine, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Celli M; Department of Nuclear Medicine, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Casadei C; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Lolli C; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Schepisi G; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Bleve S; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Brighi N; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Cursano MC; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Paganelli G; Department of Nuclear Medicine, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Matteucci F; Department of Nuclear Medicine, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., De Giorgi U; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy.
Publikováno v: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2024 Aug 29. Date of Electronic Publication: 2024 Aug 29.
Zobrazit plný text záznamu
5
Akademický článek
A Head-to-Head Comparison of the First-Line Treatments for Locally Advanced or Metastatic Urothelial Cancer: Is There Still a Role for Chemotherapy?
Autor: Gasperoni L; Oncological Pharmacy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Del Bono L; Azienda Ospedaliera Universitaria Pisana, 56100 Pisa, Italy.; School of Specialization in Hospital Pharmacy, Department of Pharmacy, University of Pisa, 56100 Pisa, Italy., Ossato A; Department of Pharmaceutical and Pharmacological Sciences, University of Padua, 35131 Padova, Italy., Giunta EF; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Messori A; HTA Unit, Regional Health Service, 50139 Florence, Italy., Damuzzo V; Hospital Pharmacy, Vittorio Veneto Hospital, 31029 Vittorio Veneto, Italy.; Italian Society of Clinical Pharmacy and Therapeutics (SIFaCT), 10123 Turin, Italy.
Publikováno v: Cancers [Cancers (Basel)] 2024 Jun 29; Vol. 16 (13). Date of Electronic Publication: 2024 Jun 29.
Zobrazit plný text záznamu
6
Akademický článek
New-generation androgen receptor signaling inhibitors (ARSIs) in metastatic hormone-sensitive prostate cancer (mHSPC): pharmacokinetics, drug-drug interactions (DDIs), and clinical impact.
Autor: Gasperoni L; Oncological Pharmacy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola (FC), Italy., Giunta EF; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola (FC), Italy., Montanari D; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola (FC), Italy., Masini C; Oncological Pharmacy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola (FC), Italy., De Giorgi U; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola (FC), Italy.
Publikováno v: Expert opinion on drug metabolism & toxicology [Expert Opin Drug Metab Toxicol] 2024 Jun; Vol. 20 (6), pp. 491-502. Date of Electronic Publication: 2024 May 22.
Zobrazit plný text záznamu
7
Akademický článek
Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis.
Autor: Messina C; Oncology Unit, ARNAS Civico, Palermo, Italy., Giunta EF; IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola, Italy., Signori A; Section of Biostatistics, Department of Health Sciences, University of Genoa, Genoa, Italy., Rebuzzi SE; Medical Oncology Unit, Ospedale San Paolo, Savona, Italy; Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy., Banna GL; Department of Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK; Faculty of Science and Health, School of Pharmacy and Biomedical Science, University of Portsmouth, Portsmouth, UK., Maniam A; Department of Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK., Buti S; Medical Oncology Unit, University Hospital of Parma, Parma, Italy; Department of Medicine and Surgery, University of Parma, Parma, Italy., Cattrini C; SCDU Oncologia, AOU Maggiore della Carità, Novara, Italy., Fornarini G; Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Bauckneht M; Section of Biostatistics, Department of Health Sciences, University of Genoa, Genoa, Italy; Nuclear Medicine, IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Greystoke A; Translational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK., Plummer R; Translational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK., Oing C; Translational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK; Mildred Scheel Cancer Career Centre HaTriCS4, University Cancer Centre Hamburg, University Medical Centre Eppendorf, Hamburg, Germany., Rescigno P; Translational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK; Candiolo Cancer Institute FPO-IRCCS, Candiolo, Italy. Electronic address: pasquale.rescigno@newcastle.ac.uk.
Publikováno v: European urology oncology [Eur Urol Oncol] 2024 Apr; Vol. 7 (2), pp. 179-188. Date of Electronic Publication: 2023 Aug 12.
Zobrazit plný text záznamu
8
Akademický článek
Neoadjuvant Chemo-Immunotherapy for Early-Stage Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Autor: Banna GL; Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom.; Faculty of Science and Health, School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, United Kingdom., Hassan MA; Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom., Signori A; Department of Health Sciences, University of Genoa, Genoa, Italy., Giunta EF; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori,' Meldola, Italy., Maniam A; Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom., Anpalakhan S; Department of Oncology, Southampton General Hospital, Southampton, United Kingdom., Acharige S; Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom., Ghose A; Department of Medical Oncology, Barts Cancer Centre, St Bartholomew's Hospital, London, United Kingdom., Addeo A; Oncology Service, Geneva University Hospital, Geneva, Switzerland.
Publikováno v: JAMA network open [JAMA Netw Open] 2024 Apr 01; Vol. 7 (4), pp. e246837. Date of Electronic Publication: 2024 Apr 01.
Zobrazit plný text záznamu
9
Akademický článek
177Lu-PSMA therapy in metastatic prostate cancer: An updated review of prognostic and predictive biomarkers.
Autor: Giunta EF; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy. Electronic address: emiliofrancescogiunta@gmail.com., Brighi N; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Gurioli G; Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Matteucci F; Nuclear Medicine Operative Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Paganelli G; Nuclear Medicine Operative Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., De Giorgi U; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy.
Publikováno v: Cancer treatment reviews [Cancer Treat Rev] 2024 Apr; Vol. 125, pp. 102699. Date of Electronic Publication: 2024 Feb 17.
Zobrazit plný text záznamu
10
Akademický článek
Instrumental activities of daily living in older patients with metastatic prostate cancer: results from the meet-URO network ADHERE prospective study.
Autor: Fratino L; Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy., Polesel J; Unit of Cancer Epidemiology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy., Giunta EF; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Maruzzo M; Medical Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy., Buti S; Oncology Unit, University Hospital of Parma, Parma, Italy.; Department of Medicine and Surgery, University of Parma, Parma, Italy., Hassan MA; Portsmouth Hospitals University NHS Trust, Portsmouth, PO6 3LY, UK.; Faculty of Science and Health, School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, PO1 2UP, UK., Basso U; Medical Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy., Rebuzzi SE; Medical Oncology Unit, Ospedale San Paolo, Savona, Italy.; Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova, Genoa, Italy., De Giorgi U; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Cinausero M; Department of Oncology, ASUFC Santa Maria Della Misericordia, Udine, Italy., Lipari H; Division of Medical Oncology, Cannizzaro Hospital, Catania, Italy., Gamba T; Medical Oncology, Mauriziano Hospital, Turin, Italy., Bimbatti D; Medical Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy., Dri A; Department of Oncology, ASUFC Santa Maria Della Misericordia, Udine, Italy.; Department of Medicine, University of Udine, Udine, Italy., Ermacora P; Department of Oncology, ASUFC Santa Maria Della Misericordia, Udine, Italy., Vignani F; Medical Oncology, Mauriziano Hospital, Turin, Italy., Fornarini G; Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Rescigno P; Candiolo Cancer Institute, FPO-IRCCS, SP142, km 3,95, 10060, Candiolo, Turin, Italy. Pasquale.rescigno@ircc.it., Banna GL; Portsmouth Hospitals University NHS Trust, Portsmouth, PO6 3LY, UK.; Faculty of Science and Health, School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, PO1 2UP, UK.
Publikováno v: Scientific reports [Sci Rep] 2024 Feb 28; Vol. 14 (1), pp. 4949. Date of Electronic Publication: 2024 Feb 28.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje